DeBaun, MR;
Kirkham, FJ;
(2016)
Central nervous system complications and management in sickle cell disease.
Blood
, 127
(7)
pp. 829-838.
10.1182/blood-2015-09-618579.
Preview |
Text (Article)
addl_pappdf8996071 1_11_2016.pdf - Accepted Version Download (658kB) | Preview |
Preview |
Text (Supplemental material)
Kirkham_CNS Complications and Management in SCD A Review DeBaun and Kirkham - Supplemental Material 01-17-16 final.pdf Download (560kB) | Preview |
Abstract
With advances in brain imaging and completion of randomized clinical trials (RCTs) for primary and secondary stroke prevention, the natural history of central nervous system (CNS) complications in sickle cell disease (SCD) is evolving. In order of current prevalence, the primary CNS complications include silent cerebral infarcts (39% by 18 years), headache (both acute and chronic: 36% in children with sickle cell anemia [SCA]), ischemic stroke (as low as 1% in children with SCA with effective screening and prophylaxis, but ∼11% in children with SCA without screening), and hemorrhagic stroke in children and adults with SCA (3% and 10%, respectively). In high-income countries, RCTs (Stroke Prevention in Sickle Cell Anemia [STOP], STOP II) have demonstrated that regular blood transfusion therapy (typically monthly) achieves primary stroke prevention in children with SCA and high transcranial Doppler (TCD) velocities; after at least a year, hydroxycarbamide may be substituted (TCD With Transfusions Changing to Hydroxyurea [TWiTCH]). Also in high-income countries, RCTs have demonstrated that regular blood transfusion is the optimal current therapy for secondary prevention of infarcts for children with SCA and strokes (Stroke With Transfusions Changing to Hydroxyurea [SWiTCH]) or silent cerebral infarcts (Silent Infarct Transfusion [SIT] Trial). For adults with SCD, CNS complications continue to be a major cause of morbidity and mortality, with no evidence-based strategy for prevention.
| Type: | Article |
|---|---|
| Title: | Central nervous system complications and management in sickle cell disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1182/blood-2015-09-618579 |
| Publisher version: | http://dx.doi.org/10.1182/blood-2015-09-618579 |
| Language: | English |
| Additional information: | This research was originally published in Blood. Michael R. DeBaun and Fenella J. Kirkham. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829-838. Copyright © the American Society of Hematology. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Neurosciences Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1476774 |
Archive Staff Only
 |
View Item |
